-
-
-
-
-
-
-
Immuneering reports Q1 2026 financial results and clinical updates
-
-
-
-
-
-
-
Teva Pharma (TEVA) Tops Q4 EPS by 31c, Beats on Revenue; Offers FY26 Revenue Guidance
-
-
-
-
-
-
-
Goldman Sachs initiates coverage on generic drugmakers, sees upside in Teva and Am
-
-
-
-
-
-
-
Teva Pharma (TEVA) Tops Q2 EPS by 6c; raises guidance
-
-
-
-
-
-
-
Teva to Host Conference Call to Discuss First Quarter 2024 Financial Results at 8 a.m. ET on May 8, 2024
-
-
-
-
-
-
-
Teva says Israel-Hamas war not hurting production, eyes growth in 2024
-
-
-
-
-
-
-
Immuneering Reports Second Quarter 2023 Financial Results and Provides Business Updates
-
1,239,354 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


